secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZIMMER BIOMET HOLDINGS, INC. (ZBH)
CIK:        0001136869
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0000950170-25-014972
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zimmer Biomet Q4 sales $2.02B (+4.9% CC), adj. EPS $2.31; guides FY2025 adj. EPS $8.15-$8.35
--------------------------------------------------------------------------------

- Q4 net sales $2.023B (+4.9% constant currency); Q4 adjusted diluted EPS $2.31.
- Full-year net sales $7.679B (+4.8% CC); full-year adjusted diluted EPS $8.00.
- FY2025 guidance: constant currency revenue growth 3%-5%; adjusted diluted EPS $8.15-$8.35.
- Announced definitive agreement to acquire Paragon 28 (FNA) for foot & ankle segment; terms not disclosed.
- Received FDA PMA for Oxford Cementless Partial Knee and FDA 510(k) for OsseoFit Stemless Shoulder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1136869/000095017025014972/0000950170-25-014972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1136869/000095017025014972/zbh-20250206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-014972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer